BEIJING--(BUSINESS WIRE)--ChinaBio^® LLC and EBD Group, co-producers of the ChinaBio^® Partnering Forum, held May 11–12 in Beijing, today announced that the 2011 edition of the event grew by 19% over last year’s conference. This year’s event was host to 658 attendees from 370 companies and 25 countries who engaged in more than 800 one-to-one meetings. These results position ChinaBio^® Partnering Forum as the largest and most productive life science conference in China.

ChinaBio^® Partnering Forum was created to bring together China life science companies seeking partnerships and with global pharma and biotech companies from Europe, the United States and the rest of the world.

The theme of this year’s ChinaBio^® Partnering Forum was “Capturing Innovation”, and the event featured the first Innovation Showcase that profiled 29 leading researchers from China’s top universities and institutes presenting their novel discoveries. Interest was high among the attendees in the presentations which showcased 15 novel drugs, four diagnostics and 10 other technologies.

On a parallel track, 38 life science companies presented detailed overviews of their technologies and business strategies to prospective partners and investors. Among the presenting companies were 13 enterprises from China.

“The third ChinaBio^® Partnering Forum built upon the success of our previous conferences, bringing more life science executives together in China than ever before,” said Greg Scott, CEO and founder of ChinaBio^® LLC. “With approximately one third of our attendees from outside China, the ChinaBio^® Partnering Forum is now the largest and most international conference focused on life science in China.”

“We were very pleased by the high level of partnering activity at the conference,” added Carola Schropp, President of EBD Group. “With over 2,500 meeting requests and over 800 one-to-one meetings, it’s apparent that our Chinese participants are successfully leveraging our partneringONE^® system to identify potential partners from around the world.”

Partnering has become a significant component of China’s explosive biopharma industry. The number of partnering deals has grown 24% over the last two years, with co-development deals the fastest growing segment, according to data from ChinaBio LLC’s research team. The rapid increase has been driven by China’s robust pipeline of over 3,200 novel molecules, nearly 200 of which are in clinical development.

The Fourth Annual ChinaBio^® Partnering Forum will be held in Suzhou next year, and is expected to exceed 750 attendees. More information about both this year’s and next year’s events is available at www.ebdgroup.com/cbpf.

About EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:

• BIO-Europe^® and BIO-Europe Spring^®, the world's largest stand-alone life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
• BioPharm America™, EBD Group’s North American partnering event
• EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry
• BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
• ChinaBio^® Partnering Forum, the first dedicated biotech/pharma partnering conference in China co-produced with ChinaBio^® LLC.

EBD Group’s sophisticated web-based partnering service, partneringONE^®, is used as the partnering engine at numerous third-party events around the world. EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com.

About ChinaBio^® LLC

Since its founding in January, 2007, ChinaBio^® LLC has rapidly created a broad platform of capabilities connecting China life science with the world. ChinaBio has helped global life science companies identify over 400 licensing and acquisition opportunities in China and China companies raise nearly $400 million.

• Conferences: ChinaBio organizes the premier life science investment and partnering conferences in China, having attracted over 4,000 attendees.
• Consulting: ChinaBio works with global life science companies and China entrepreneurs to define and execute a successful global strategy.
• Capital: ChinaBio Capital Partners helps companies secure partnerships and acquisitions and access private and government funding in China.
• Publishing: ChinaBio^® Today is the most widely read online and email newsletter on China’s life science industry, with over 18,000 readers.

More information is available at www.ChinaBioLLC.com.

Contacts